|
|
 |
|
|
Your Plan can expect to face a significant number of urologic claims this year. Fortunately, UroCor LabsSM represents the cutting edge in quality services and cost effectiveness in urology. Disease-specific focus eliminates inefficiences, reduces overall costs and substantially improves patient outcomes.
|
|
|
|
Urologic Incidence Rates
|
|
|
|
|
|
Prostate Cancer'
|
Bladder Cancer'
|
New Stone Patients'
|
|
|
Male Only
|
Male Female
|
Male Female
|
|
All Ages
|
123.0
|
5.7 1.7
|
101.1 101.1
|
|
Under 65
|
26.7
|
1.1 0.4
|
|
|
Over 65
|
1002.2
|
46.7 13.7
|
|
|
|
|
|
' Incidence Rates per 100,000; SEER Cancer Statistics & Review, NIH, NCI
|
|
|
|
- Specializing solely in the field of urology
- Serving over one-third of all office-based urologists
- Analyzing more than 400,000 urological cases per year
- Focusing on prostate cancer, bladder cancer and stone disease
- Proprietary diagnostics
|
|
|
|
By combining clinical and anatomic pathology services with unequaled expertise, UroCor LabsSM consistently delivers definitive diagnoses which:
- Reduce additional or unnecessary testing
- Decrease the overall cost of care
- Produce better outcomes and greater member satisfaction
|
|
